In a woman with known pulmonary hypertension, what postpartum complications should be anticipated and what should be monitored after delivery?

Postpartum Management of Pulmonary Hypertension

Critical Immediate Postpartum Period (First 24-72 Hours)

The immediate postpartum period carries the highest risk for acute right ventricular failure and maternal death in women with pulmonary hypertension, requiring intensive hemodynamic monitoring for at least 24 hours after delivery. 1, 2, 3

Hemodynamic Crisis Window

• Marked volume shifts occur immediately postpartum as the vena cava decompresses and uterine blood returns to systemic circulation, causing dramatic increases in cardiac filling pressures and pulmonary artery pressure. 1
• Acute pulmonary hypertensive crisis occurs in approximately 10.6% of patients, with sudden circulatory collapse from cardiac decompensation being the most feared complication. 4, 5
• The mortality risk extends through the first week postpartum, with 6.4% maternal mortality reported in contemporary series despite optimal management. 4

Mandatory Intensive Monitoring Protocol

• Continuous invasive hemodynamic monitoring with pulmonary artery catheter should be employed for close titration of medical therapy during the first 24-72 hours postpartum. 1, 5
• Continuous pulse oximetry, ECG monitoring, and systemic arterial pressure monitoring are essential. 6
• Right ventricular function assessment by echocardiography should be performed immediately postpartum and serially if clinical deterioration occurs. 3

Fluid Management Strategy

Strict limitation of intravenous fluids is critical to avoid right ventricular volume overload, which can precipitate acute decompensation. 5

• Cautious fluid management with diuretics as needed should be continued from the intrapartum period. 1
• Monitor for signs of volume overload including rising central venous pressure, worsening tricuspid regurgitation, and declining oxygen saturation. 5

Uterotonic Agent Selection

Methylergonovine (Methergine) is absolutely contraindicated in the postpartum period due to >10% risk of severe vasoconstriction and hypertension, which can precipitate pulmonary hypertensive crisis. 6

Safe Uterotonic Protocol

• Administer oxytocin as a slow intravenous infusion (<2 U/min or approximately 33 mU/min) after placental delivery to prevent postpartum hemorrhage while avoiding systemic hypotension. 6
• Avoid rapid IV bolus administration of oxytocin, as this causes severe hypotension, tachycardia, and can worsen right ventricular function. 6
• If additional uterotonics are needed for hemorrhage, prostaglandin F analogues (carboprost) may be used cautiously, though they can increase pulmonary artery pressure. 6
• Tranexamic acid 1g IV over 10 minutes should be administered early (within 3 hours) for clinically diagnosed postpartum hemorrhage, with a second dose available if bleeding persists after 30 minutes. 6

Pulmonary Hypertension-Specific Therapy

Continue or intensify pulmonary arterial hypertension-targeted medications throughout the postpartum period, as abrupt discontinuation can precipitate acute decompensation. 7, 2

• Intravenous epoprostenol should be available for acute management of spontaneous rises in pulmonary vascular resistance that commonly occur postpartum. 5
• Inhaled nitric oxide, intravenous prostacyclins, and oral calcium channel blockers (if previously responsive) should be continued or initiated as needed. 1
• The improvement of pulmonary hemodynamics with PAH therapy prior to delivery correlates with more favorable outcomes after delivery. 7

Mechanical Circulatory Support Readiness

Extracorporeal membrane oxygenation (ECMO) should be immediately available for patients who develop sudden circulatory collapse, as mechanical support may be necessary to mitigate hemodynamics and extend cardiac recovery time. 2

• Have a low threshold for initiating mechanical support given the high mortality risk during acute decompensation. 2
• Multidisciplinary team including pulmonary hypertension specialists, high-risk obstetrics, cardiovascular anesthesiology, and cardiac intensive care should remain actively involved. 1, 2

Anticoagulation Management

Resume therapeutic anticoagulation cautiously in the postpartum period, balancing thromboembolism risk against postoperative bleeding risk. 5

• Subcutaneous enoxaparin or other anticoagulation should be restarted once surgical hemostasis is confirmed and bleeding risk is acceptable. 5
• Monitor closely for abdominal bleeding related to postoperative anticoagulation and platelet dysfunction, which may require transfusion and temporary discontinuation. 5

Specific Complications to Monitor

Right Ventricular Failure (Most Common)

• Heart failure develops in approximately 35% of postpartum patients with pulmonary hypertension, manifesting as worsening dyspnea, hypoxemia, hypotension, and elevated jugular venous pressure. 4
• Treat with inotropic agents (dobutamine), supplemental oxygen, diuretics, and intensification of pulmonary vasodilator therapy. 1

Pulmonary Hypertensive Crisis

• Acute rise in pulmonary vascular resistance occurs unpredictably in the immediate postpartum period. 5
• Requires immediate treatment with intravenous prostacyclins, inhaled nitric oxide, and consideration of mechanical support. 5

Arrhythmias

• Atrial and ventricular arrhythmias can precipitate hemodynamic collapse in the setting of right ventricular dysfunction. 3
• Maintain continuous cardiac monitoring and have antiarrhythmic medications readily available. 3

Extended Postpartum Monitoring

The hemodynamic changes associated with pregnancy regress by approximately 6 weeks after delivery, requiring continued close monitoring throughout this period. 1

• Outpatient follow-up should occur within 48-72 hours of discharge, again at 7-14 days, and at 6 weeks postpartum. 8
• Serial echocardiography and functional assessment should be performed to ensure pulmonary hemodynamics are returning toward baseline. 7
• Some women experience progressive pulmonary hypertension during pregnancy that remains worse after pregnancy, requiring long-term intensification of therapy. 1

Common Pitfalls to Avoid

• Do not administer methylergonovine under any circumstances, as vasoconstriction can be catastrophic. 6
• Do not give rapid IV bolus oxytocin; always use slow infusion to prevent hypotension. 6
• Do not liberalize fluid administration assuming the patient is "post-delivery"; right ventricular volume overload remains a critical risk. 5
• Do not discharge patients early; the highest mortality risk extends through the first week postpartum. 4, 3
• Do not discontinue pulmonary hypertension medications; continue or intensify therapy throughout the postpartum period. 7, 2